These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30231371)

  • 21. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.
    Lau PKH; Cullinane C; Jackson S; Walker R; Smith LK; Slater A; Kirby L; Patel RP; von Scheidt B; Slaney CY; McArthur GA; Sheppard KE
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Current and Pipeline Drugs for Treatment of Melanoma.
    Natarelli N; Aleman SJ; Mark IM; Tran JT; Kwak S; Botto E; Aflatooni S; Diaz MJ; Lipner SR
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
    Johnson DB; Sosman JA
    JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma.
    Comito F; Pagani R; Grilli G; Sperandi F; Ardizzoni A; Melotti B
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in managing metastatic melanoma: which treatment when?
    Amaral T; Meraz-Torres F; Garbe C
    Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of systemic therapies in the management of melanoma brain metastases.
    Lyle M; Long GV
    Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Emerging Therapeutic Landscape of Advanced Melanoma.
    Henriques V; Martins T; Link W; Ferreira BI
    Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting immuno-oncology-based drug combinations - what should we be considering?
    Festino L; Vanella V; Trojaniello C; Ascierto PA
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Systemic treatment of inoperable metastasized malignant melanoma].
    Gutzmer R; Rauschenberg R; Meier F
    Hautarzt; 2016 Jul; 67(7):529-35. PubMed ID: 27164828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
    Christiansen SA; Khan S; Gibney GT
    Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
    J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ; Rizos H; Scolyer RA; Long GV
    Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.
    Assi HI; Assi RE
    Curr Cancer Drug Targets; 2017; 17(2):137-157. PubMed ID: 27628745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
    Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
    J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.